New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2013
14:31 EDTAMRNAmarin weakness unwarranted, says Leerink
Leerink believes that Amarin is weak today due to a negative Seeking Alpha article that provides no new information. The firm thinks it's too early to deem the company's Vascepa launch a commercial failure and sees FDA acceptance of the Vascepa sNDA in mixed dyslipidemia in late April/early May as an important catalyst. The firm maintains an Outperform rating.
News For AMRN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for AMRN

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use